10x Genomics, Inc. (TXG)
$
20.2
-0.60 (-2.97%)
Key metrics
Financial statements
Free cash flow per share
0.6506
Market cap
2.6 Billion
Price to sales ratio
4.1013
Debt to equity
0.1108
Current ratio
4.4787
Income quality
-1.1599
Average inventory
65.5 Million
ROE
-0.1026
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
10x Genomics, Inc., a life science technology company, specializes in developing and selling instruments, consumables, and software for the analysis of biological systems across North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company recorded an operating income of -$194,559,000.00 reflecting its earnings from core operations. With a gross profit ratio of 0.68 it showcases the efficiency of its production and sales operations. In addition to core operations, the company earned an interest income of $18,448,000.00 showcasing its financial investments. It incurred an income tax expense of $4,927,000.00 indicating its tax obligations. The total costs and expenses for the company are $805,344,000.00 reflecting its overall spending. 10x Genomics offers a range of products such as the Chromium and Chromium Connect instruments, microfluidic chips, slides, reagents, and other consumables. Its single-cell solutions, which operate on its chromium instruments, include single-cell gene expression for precise measurement of gene activity on an individual cell basis, single-cell immune profiling for assessing immune cell activity and their targets, and single-cell Assay for Transposase Accessible Chromatin (ATAC) for analyzing epigenetics related to DNA organization. Additionally, the single-cell multiome ATAC + gene expression solution allows researchers to analyze both genetic activity and epigenetic programming within the same cells across tens of thousands of cells in a single experiment. Furthermore, it provides the Visium spatial gene expression solution, which enables spatial analysis of gene expression patterns in a single tissue sample, and combined gene expression and protein co-detection with immunofluorescence. The stock is affordable at $13.04 making it suitable for budget-conscious investors. With a high average trading volume of 2,683,795.00 the stock indicates strong liquidity, which is beneficial for investors looking to enter and exit positions with ease. With a market capitalization of $2,556,371,671.00 the company is classified as a small-cap player, highlighting its growth potential in the market. It is a key player in the Medical - Healthcare Information Services industry, contributing significantly to the overall market landscape. Moreover, it belongs to the Healthcare sector, driving innovation and growth within its field. This combination of affordability, liquidity, and market significance positions 10x Genomics as an attractive option for various types of investors.
Is 10x Genomics, Inc. (TXG) a good investment?
Investing in 10x Genomics, Inc. (TXG) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is 10x Genomics, Inc. (TXG)'s stock forecast?
Analysts predict 10x Genomics, Inc. stock to fluctuate between $6.78 (low) and $23.56 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is 10x Genomics, Inc.'s market capitalization?
As of 2026-01-30, 10x Genomics, Inc.'s market cap is $2,556,371,671, based on 126,553,053 outstanding shares.
How does 10x Genomics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, 10x Genomics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy 10x Genomics, Inc. (TXG) stock?
To buy 10x Genomics, Inc. (TXG) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TXG. Place an order (Market, Limit, etc.).
What is the best time to invest in 10x Genomics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has 10x Genomics, Inc. stock ever split?
10x Genomics, Inc.'s last stock split was 1:2 on 2006-07-17.
How did 10x Genomics, Inc. perform in the last earnings report?
Revenue: $610,785,000 | EPS: -$1.52 | Growth: -30.28%.
Where can I find 10x Genomics, Inc.'s investor relations reports?
Visit https://www.10xgenomics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for 10x Genomics, Inc.?
You can explore historical data from here
What is the all-time high and low for 10x Genomics, Inc. stock?
All-time high: $191.15 (2021-09-07) | All-time low: $6.78 (2025-04-07).
What are the key trends affecting 10x Genomics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
PLEASANTON, Calif., Jan. 11, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2025.
defenseworld.net
10x Genomics (NASDAQ: TXG - Get Free Report) and iRhythm Technologies (NASDAQ: IRTC - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Profitability This table compares 10x Genomics and
seekingalpha.com
10x Genomics, Inc. ( TXG ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Cassie Corneau - Manager of Investor Relations & Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Adam Taich - CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Madeline Mollman Puneet Souda - Leerink Partners LLC, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division David Westenberg - Piper Sandler & Co., Research Division Kyle Boucher - TD Cowen, Research Division Lu Li - UBS Investment Bank, Research Division Michael Ryskin - BofA Securities, Research Division Justin Bowers - Deutsche Bank AG, Research Division Jaden Rismay - JPMorgan Chase & Co, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Benjamin Mee - Stephens Inc., Research Division Presentation Operator Thank you for standing by. Welcome to the 10X Genomics' Third Quarter 2025 Earnings Conference Call.
zacks.com
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
fool.com
Lancaster Investment Management bought over 620,000 shares in 10x Genomics (TXG) worth around $7.27 million. 10x Genomics, a new holding for the investment manager, now accounts for 3.1% of its AUM.
zacks.com
10x Genomics (TXG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
prnewswire.com
Collaboration enables researchers to begin exploring 10x single cell tools and datasets conversationally, with spatial applications to follow - making advanced analysis more accessible to the broader researcher community PLEASANTON, Calif. , Oct. 20, 2025 /PRNewswire/ -- 10x Genomics, Inc.
zacks.com
10x Genomics (TXG) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
seekingalpha.com
10x Genomics, Inc. (NASDAQ:TXG ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Adam S. Taich - CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Cassie Corneau - Manager of Investor Relations & Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Jacob Krahenbuhl - William Blair & Company L.L.C.
zacks.com
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
See all news
